• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Establishment Labs Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Other Events, Financial Statements and Exhibits

    5/22/25 5:10:52 PM ET
    $ESTA
    Industrial Specialties
    Health Care
    Get the next $ESTA alert in real time by email
    esta-20250520
    Building B15 and 25Coyol Free ZoneAlajuelaCosta RicaNasdaq5062434 24000001688757false00016887572025-05-202025-05-20

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    May 20, 2025
    Date of Report (date of earliest event reported)
    Establishment Labs Holdings Inc.
    (Exact name of registrant as specified in its charter)
    British Virgin Islands001-38593
    98-1436377
    (State or other jurisdiction of
    incorporation or organization)
    (Commission File No.)
    (I.R.S. Employer
    Identification Number)
    Building B15 and 25
    Coyol Free Zone
    Alajuela
    Costa Rica
    (Address of principal executive offices) (Zip Code)
    +506 2434 2400
    (Registrant’s telephone number, including area code)
    N/A
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading symbolName of each exchange on which registered
    Common Shares, No Par ValueESTA
    The Nasdaq Capital Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2) of this chapter.
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 4.01 Changes in Registrant’s Certifying Accountant.
    (a) Resignation of Independent Registered Public Accounting Firm
    On November 1, 2024, CBIZ CPAs P.C. (“CBIZ”) acquired the attest business of Marcum LLP (“Marcum”), and substantially all of the partners and staff that provided attestation services with Marcum joined CBIZ in connection with the acquisition. Accordingly, on May 20, 2025, as a result of the acquisition, Marcum resigned as the independent registered public accounting firm of Establishment Labs Holdings, Inc. (the “Company”) and, on the same day, the Audit Committee of the Company’s Board of Directors (the “Audit Committee”) approved the appointment of CBIZ as the Company’s independent registered public accounting firm.
    The audit reports of Marcum on the Company’s consolidated financial statements for the years ended December 31, 2024, and December 31, 2023, did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles.
    During the fiscal years ended December 31, 2024, and December 31, 2023, and the subsequent interim period through May 20, 2025, there were (i) no “disagreements” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) between the Company and Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to the subject matter of the disagreements in connection with its reports on the Company’s consolidated financial statements for such years and (ii) no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K) other than a material weakness in internal controls over information technology general controls for the fiscal year ended December 31, 2023, as disclosed in Part II, Item 9A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
    The Company provided Marcum with a copy of the above disclosures and requested that Marcum furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made above and, if it does not agree, the respects in which it does not agree. A copy of Marcum’s letter, dated May 21, 2025, is attached as Exhibit 99.1 to this Current Report on Form 8-K.
    (b) Approval of New Independent Registered Public Accounting Firm
    On May 20, 2025, the Audit Committee approved the appointment of CBIZ as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. In connection with the engagement, CBIZ will prepare the report on the Company’s consolidated financial statements for the fiscal year ending December 31, 2025. During the fiscal years ended December 31, 2024, and December 31, 2023, and the subsequent interim period through May 20, 2025, neither the Company nor anyone on its behalf has consulted with CBIZ regarding (i) the application of accounting principles to a specific completed or contemplated transaction or regarding the type of audit opinions that might be rendered by CBIZ on the Company’s consolidated financial statements, and neither a written report nor oral advice was provided by CBIZ to the Company that CBIZ concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, or (ii) any matter that was either the subject of a “disagreement” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or a “reportable event” (as defined in Item 304(a)(1)(v) of Regulation S-K).

    Item 8.01 Other Information.
    In connection with the appointment of CBIZ as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 as disclosed in Item 4.01 above, on May 21, 2025 the Company filed a proxy supplement for its 2025 annual meeting of stockholders to be held on May 23, 2025 to amend and replace in the proxy statement that was originally filed on April 10, 2025 (the “Definitive Proxy Statement”) the name of the independent registered public accounting firm in Proposal No. 2 to the Definitive Proxy Statement (seeking ratification of the Company’s independent registered public accounting firm) and in the sample proxy card included in the Definitive Proxy Statement.




    Item 9.01 Financial Statements and Exhibits.
    (d) Exhibits
    Exhibit No.Description
    99.1
    Letter from Marcum LLP to the Securities and Exchange Commission, dated May 21, 2025.
    104Cover Page Interactive Data File (embedded within the Inline XBRL document).






    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
    ESTABLISHMENT LABS HOLDINGS INC.
    Dated:
    May 22, 2025
    By:
    /s/ Rajbir S. Denhoy
    Name:
    Rajbir S. Denhoy
    Title:
    Chief Financial Officer

    Get the next $ESTA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ESTA

    DatePrice TargetRatingAnalyst
    5/16/2025$62.00Buy
    BTIG Research
    5/14/2025$48.00Hold → Buy
    Needham
    4/14/2025Hold
    Needham
    5/22/2024$60.00Buy → Neutral
    Citigroup
    8/31/2023$75.00Overweight
    JP Morgan
    6/29/2023$79.00Buy
    Citigroup
    10/14/2022$90.00Overweight
    Stephens
    10/13/2022$70.00Buy
    Mizuho
    More analyst ratings

    $ESTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Establishment Labs with a new price target

      BTIG Research initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $62.00

      5/16/25 8:05:11 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs upgraded by Needham with a new price target

      Needham upgraded Establishment Labs from Hold to Buy and set a new price target of $48.00

      5/14/25 8:49:26 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Needham initiated coverage on Establishment Labs

      Needham initiated coverage of Establishment Labs with a rating of Hold

      4/14/25 7:48:56 AM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    SEC Filings

    See more
    • Establishment Labs Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

      6/12/25 1:00:50 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

      5/27/25 4:12:22 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Other Events, Financial Statements and Exhibits

      8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

      5/22/25 5:10:52 PM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lewin Nicholas Sheridan bought $54,073 worth of shares (2,000 units at $27.04), increasing direct ownership by 0.19% to 1,064,888 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      12/15/23 7:59:37 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Lewin Nicholas Sheridan bought $110,000 worth of shares (5,000 units at $22.00) (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      11/21/23 8:00:55 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Denhoy Raj bought $49,972 worth of shares (2,250 units at $22.21), increasing direct ownership by 38% to 8,112 units (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      11/20/23 8:00:42 AM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Establishment Labs Appoints Peter Caldini as Chief Executive Officer

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision

      5/7/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Announces CEO Transition

      Peter Caldini to become Interim CEO effective March 1, 2025 Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date. Mr. Chacón-Quirós will continue with Establishment Labs as both a board member and an active

      1/13/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants in the U.S. later this year. "Jeff is the ideal person to introduce Motiva to the United States," said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs. "Just as we have changed the standard for breast augmentat

      5/1/24 8:30:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Financials

    Live finance-specific insights

    See more
    • Establishment Labs to Announce Second Quarter 2025 Financial Results on August 7

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (416) 764 8646 (U.S. and Canada) or +1 (888) 396 8049 (International) and use conference ID number 13750829. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establ

      7/25/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Reports First Quarter 2025 Financial Results

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2025. First Quarter Highlights and Outlook First quarter worldwide revenue of $41.4 million, including $6.2 million of Motiva sales in the United States. 2025 revenue guidance maintained at $205 million to $210 million, year over year growth of 23%–26%. First quarter gross margin of 67.2% compared to 65.6% in the year-ago period. First quarter loss from operations was $16.9 million compared to a loss of $8.8 million in the ye

      5/7/25 4:00:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs to Announce First Quarter 2025 Financial Results on May 7

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2025, after the market closes on Wednesday, May 7, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750827. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establis

      4/24/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Jw Asset Management, Llc

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      7/9/25 4:01:11 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Large owner Jw Asset Management, Llc

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      7/7/25 4:05:59 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Large owner Jw Asset Management, Llc sold $430,486 worth of shares (9,700 units at $44.38) (SEC Form 4)

      4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

      7/2/25 4:01:08 PM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Establishment Labs Holdings Inc.

      SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

      11/12/24 12:54:20 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Establishment Labs Holdings Inc.

      SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

      11/12/24 9:03:38 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Establishment Labs Holdings Inc. (Amendment)

      SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

      2/14/24 4:51:40 PM ET
      $ESTA
      Industrial Specialties
      Health Care

    $ESTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Establishment Labs to Announce Second Quarter 2025 Financial Results on August 7

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (416) 764 8646 (U.S. and Canada) or +1 (888) 396 8049 (International) and use conference ID number 13750829. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establ

      7/25/25 8:00:00 AM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs Hosting Investor Day on June 12

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at www.establishmentlabs.com. In-person attendance at the event is limited and requires advanced registration. Please email: [email protected] for further information. About Establishment Labs Establishment Labs Holdings Inc. is

      6/11/25 7:07:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care
    • Establishment Labs to Present at Jefferies Global Healthcare Conference

      Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in the Jefferies Global Healthcare Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Wednesday, June 4, 2025 at 7:35 a.m. ET. A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. Archived versions of the webcasts will be available on the same website following the completion of the e

      6/3/25 4:30:00 PM ET
      $ESTA
      Industrial Specialties
      Health Care